Leerink analyst David Risinger notes AbbVie (ABBV) announced on November 11 that emraclidine’s pivotal Phase 2 trials, EMPOWER-1 and EMPOWER-2, did not meet their primary endpoints. The firm argues that this outcome is a clear positive positive for Bristol Myers (BMY) because its recently approved schizophrenia treatment Cobenfy will not face competition from emraclidine. Leerink has a Market Perform rating on AbbVie’s shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV: